Tirzepatide - Weight management in adults
You are here : Home > Formulary Search > Tirzepatide - Weight management in adults
Status 1
- Subcutaneous injection (sc)
Access in PRIMARY Care via a Locally Commissioned Service (which includes wrap around support) ONLY
BMI ≥ 40 kg/m2 (BMI should be adjusted by -2.5 kg/m² for individuals from ethnic backgrounds, AND at least FOUR of the five following comorbidities:
- Type 2 diabetes (T2DM), Hypertension, Dyslipidaemia, Cardiovascular disease (CVD), Obstructive sleep apnoea (OSA)
Status 2
- Subcutaneous injection (sc)
Access through the specialist weight management service at Ashford & St Peters NHS Foundation Trust ONLY for patients in phase 1 here https://www.endocrinology.org/media/sjdpporx/joint-position-statement-on-medical-therapies-for-obesity_final-resubmitted-sfe-211223.pdf
After referral SWMS will consider appropriate initiation in line with cohort 1 here PRN01879-interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-NICE-fu.pdf and will prescribe for 12 months prior to transfer of care.
Documentation
PAD Profile
Other Indications
Below are listed other indications that Tirzepatide is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Weight management in adults.
Committee Recommendations (3)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for tirzepatide initiation in secondary care for overweight and obesity management. This will enable the Surrey Weight Management Service (SWMS) to initiate appropriate patients with tirzepatide for the same cohort of patients eligible for treatment in primary care (cohort 1 as stated in the NHS E commissioning guidance.)
A BLUE (with specialist initiation from the SWMS) was agreed with prescribing by the SWMS for 12 months prior to transfer of care to primary care prescribers.
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed tirzepatide in primary care for obesity and weight management in line with NICE TA1026.
Tirzepatide in Surrey Heartlands will be available via primary care for patients who fall within the Funding Variation criteria detailed within the NHS England Commissioning Guidance as a GREEN traffic light status via a Locally Commissioned Service (which will include wrap around support).
BMI ≥ 40 kg/m2 (BMI should be adjusted by -2.5 kg/m² for individuals of South Asian, Chinese, other Asian, Middle Eastern, Black African or African–Caribbean ethnic backgrounds, due to increased cardiometabolic risk at lower BMI levels) AND at least four of the five following comorbidities:
- Type 2 diabetes (T2DM)
- Hypertension
- Dyslipidaemia
- Cardiovascular disease (CVD)
- Obstructive sleep apnoea (OSA)
NB: Tirzepatide weekly injection for use in Type 2 Diabetes should ONLY be used when the primary indication is diabetic control to allow for equity of access to tirzepatide for weight management in line with the national funding variation cohorts. The agreement made in March 2024 by the APC is available here for patients with Type 2 Diabetes: https://surrey.res.services/PAD/Profile/Index/6604
GLP-1 receptor agonists can impact female hormones, including HRT and contraceptives, and reproductive health through various mechanisms. For further information and advice see links below.